Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + rituximab versus bendamustine + rituximab in previously untreated mantle cell lymphoma patients ineligible for stem cell transplantation
NL-OMON60670Phase 3Active, not recruiting
- Sponsor
- BeOne Medicines
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in mantle cell lymphoma (MCL) comparing Zanubrutinib + rituximab with Bendamustine + rituximab (2 arms). Primary endpoint: Progression-free survival. Started Jun 2021; status: active, not recruiting.
02
Drugs
zanubrutinibrituximabbendamustine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON60670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60670.